Supplemental indication approved April 20 for irinotecan as first-line treatment for metastatic colorectal cancer in combination with 5-fluorouracil/leucovorin. An FDA "Talk Paper" says the approval was based on studies in which "the combination of Camptosar and 5FU/LV resulted in a significant delay in the time at which tumors progressed and significant improvement in survival compared with 5-FU/LV alone." FDA's Oncologic Drugs Advisory Committee unanimously recommended approval of the combination therapy for the new indication at its March 16 meeting (1"The Pink Sheet" March 20, p. 6)
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth